Clinical Trial Update: A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. [Phase 2]

View source ↗

Summary

A Phase 2 trial in advanced non-small cell lung cancer evaluating new agents with and without docetaxel has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: WITHDRAWN